Enochian Biosciences Return on Equity

Enochian Biosciences (ENOB) currently reports a ROE of 1342.81%. That is above the Healthcare sector average of 29.33%. Use the charts on this page to explore Enochian Biosciences's ROE history and peer comparisons.

Enochian Biosciences's ROE of 1342.81% is higher than the Healthcare sector average of 29.33%. That is roughly 4478.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Enochian Biosciences's current 1342.81% should be judged against Healthcare norms (sector average: 29.33%) and against ENOB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 1342.81%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Enochian Biosciences, and consider following ENOB for alerts when major investors trade the stock.

Enochian Biosciences is classified in the Healthcare sector. On ROE, it currently shows 1342.81% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENOB with unrelated industries.